Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Trends in Pharmacological Sciences|May 26, 2024
Emerging paradigms and recent progress in targeting ErbB in cancersNicolas Stoup, Maxime Liberelle, Nicolas Lebègue, et al.Journal of Medicinal Chemistry|February 7, 2020
EGF-Containing Membrane-Bound Mucins: A Hidden ErbB2 Targeting Pathway?Maxime Liberelle, Nicolas Jonckheere, Patricia Melnyk, et al.Expert Opinion on Therapeutic Patents|July 18, 2024
Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson's disease: a patent review of the literature to dateMargaux Morez, Antonio Jesús Lara Ordóñez, Patricia Melnyk, et al.Pharmacology|October 25, 2014
Pharmacokinetic evaluation of a novel benzopyridooxathiazepine derivative as a potential anticancer agentFlorence Bourdon, Marie Lecoeur, Nicolas Lebègue, et al.International Journal of Molecular Sciences|December 23, 2023
Jacalin-Curcumin Complex Sensitizes the Breast Cancer MDA-MB-231 Cell LineLidiya Petrova, Nikolay Gergov, Marie Stoup, et al.Scientific Reports|November 15, 2019
MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale ThermophoresisMaxime Liberelle, Romain Magnez, Xavier Thuru, et al.Scientific Reports|April 15, 2020
Publisher Correction: MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale ThermophoresisMaxime Liberelle, Romain Magnez, Xavier Thuru, et al.Molecules (Basel, Switzerland)|August 29, 2024
Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor AntagonistsAmélie Laversin, Robin Dufossez, Raphaël Bolteau, et al.Cancers|November 27, 2021
The EGF Domains of MUC4 Oncomucin Mediate HER2 Binding Affinity and Promote Pancreatic Cancer Cell TumorigenesisNicolas Stoup, Maxime Liberelle, Céline Schulz, et al.European Journal of Pharmacology|March 3, 2009
S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused ratsKyung-Ah Kim Sohn, Céline Cruciani-Guglielmacci, Nadim Kassis, et al.Pageof 2